IBM Partners With Deutsche Telekom on Cloud Platform and 2 Other Dow Movers to Watch
International Business Machine Corp. (NYSE: IBM): Current price $190.45
On Tuesday, IBM and Deutsche Telekom announced their collaboration through which to provide the IBM MobileFirst platform in the cloud to small and medium-sized customers in Europe. Developer Garden, Deutsche Telekom’s developer platform, has introduced the new cloud service, Developer Garden powered IBM Worklight, which enables developers to cost-effectively and quickly create applications for all mobile platforms, bringing it to market sooner than ever before.
By offering IBM Worklight on the Deutsche Telekom cloud by means of Developer Garden, SMBs that typically might not have the resources to obtain enterprise-grade mobile tools will now get to easily consume these technologies as a service, without the need for long term investment or planning.
Hewlett-Packard Co. (NYSE:HPQ): Current price $21.47
As a part of its ongoing endeavors to enhance its product manufacturing and supply chain operations, Hewlett-Packard on Tuesday announced a greenhouse gas emissions reduction target for its first-tier manufacturing and product-transportation supply chain partners. The company’s goal, marking a first for the information tech industry, is to push for a 20-percent decrease in its first-tier manufacturing and product transportation-related greenhouse gas emissions intensity by 2020, versus 2010.
Merck & Co. Inc. (NYSE:MRK): Current price $47.85
The FDA has issued a complete response letter for Merck’s resubmitted new drug application for sugammadex sodium injection. The firm wants to get sugammadex cleared in the United States for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. The response letter from the FDA has raised fears concerning the operational aspects of a hypersensitivity study that the agency had requested the company to run. Merck had failed to obtain United States approval for sugammadex earlier in 2008, at which time the agency had asked for additional data linked with hypersensitivity reactions and bleeding events.